Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers

被引：0
|
作者：
Labidi-Galy, S. I. [1 ]
Rouge, T. deLa Motte [2 ]
Derbel, O. [3 ]
Wolfer, A. [4 ]
Kalbacher, E. [5 ]
Olivier, T. [1 ]
Combes, J-D. [6 ]
Hu-Heimgartner, K. [1 ]
Tredan, O. [7 ]
Guevara, H. [7 ]
Heinzelmann-Schwarz, V. [8 ]
Fehr, M. [9 ]
de Castelbajac, V. [10 ]
Vaflard, P. [11 ]
Crivelli, L. [12 ]
Bonadona, V. [7 ]
Viassolo, V. [1 ]
Bazan, F. [13 ]
Rodrigues, M. [14 ]
Ray-Coquard, I. L. [7 ]
机构：
[1] HUG, Dept Oncol, Geneva, Switzerland
[2] Ctr Eugene Marquis, Dept Med Oncol, Rennes, France
[3] Hop Prive Jean Mermoz, Inst Canc, Lyon, France
[4] CHU Vaudois, Dept Oncol, Lausanne, Switzerland
[5] CHRU Besancon, Hop Jean Minjoz, Dept Oncol, Besancon, France
[6] IARC, Infect & Canc Epidemiol Grp, Lyon, France
[7] Ctr Leon Berard, Dept Med Oncol, Lyon, France
[8] Univ Spital Basel, Dept Gynecol, Basel, Switzerland
[9] Kantonsspital Frauenfeld, Frauenklin, Frauenfeld, Switzerland
[10] Inst Curie, Dept Oncol, Paris, France
[11] Inst Curie, Dept Med Oncol, Paris, France
[12] Ctr Eugene Marquis, Div Canc Genet, Rennes, France
[13] CHU Besancon, Hop Jean Minjoz, Doubs, Besancon, France
[14] Inst Curie, Dept Med Oncol, Paris, France
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1003P
引用
收藏
页码：410 / 410
页数：1
相关论文
共 50 条
  • [41] Factors Associated with Prolonged Survival in Destination Therapy LVAD Recipients
    Xia, Y.
    Forest, S.
    Friedmann, P.
    Chou, L.
    Patel, S.
    Jorde, U.
    Goldstein, D.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2017, 36 (04): : S183 - S183
  • [42] Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival
    Liu, Joyce
    Cristea, Mihaela C.
    Frankel, Paul
    Neuhausen, Susan L.
    Steele, Linda
    Engelstaedter, Verena
    Matulonis, Ursula
    Sand, Sharon
    Tung, Nadine
    Garber, Judy E.
    Weitzel, Jeffrey N.
    CANCER GENETICS, 2012, 205 (1-2) : 34 - 41
  • [43] Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer (PSROC) and a BRCA mutation (C-PATROL): Overall survival (OS) in predefined subgroups
    Marme, F.
    Hilpert, F.
    Welslau, M. K.
    Grabowski, J. P.
    Schneeweiss, A.
    Hartkopf, A. D.
    Becker, S.
    Bauerschlag, D.
    Fasching, P. A.
    Brandi, C.
    Rehbein, J. K.
    Glowik, R. M.
    Sehouli, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S586 - S587
  • [44] Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer
    Friedlander, Michael
    Banerjee, Susana
    Mileshkin, Linda
    Scott, Clare
    Shannon, Catherine
    Goh, Jeffrey
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 (04) : 323 - 331
  • [45] A Phase 1 Trial of Olaparib and Oral Metronomic. Cyclophosphamide in Patients with Metastatic BRCA-Associated Breast/Ovarian Cancers or Non-BRCA Associated Triple-Negative Breast Cancer/High Grade Serous Ovarian Cancers
    Friedlander, M.
    Scott, C. L.
    Lindeman, G. J.
    Gibbs, E.
    Badger, H. D.
    Paterson, R. J.
    Macnab, L.
    Zdenkowski, N.
    Kwan, E. M.
    Boyle, F. M.
    Lee, C. K.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 59 - 59
  • [46] Safety of bevacizumab and olaparib as frontline maintenance therapy in advanced ovarian cancer: expert review for clinical practice
    Romero, Ignacio
    Guerra, Eva
    Madariaga, Ainhoa
    Manso, Luis
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [47] THE CLINICAL OUTCOMES OF NEOADJUVANT THERAPY WITH CISPLATIN PLUS MITOMYCIN IN BRCA1-MUTATED OVARIAN CANCER
    Kotiv, K.
    Sokolenko, A.
    Ulrikh, E.
    Sidoruk, A.
    Ivantsov, A.
    Gorodnova, T.
    Urmancheeva, A.
    Berlev, I.
    Imyanitov, E.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A532 - A532
  • [48] The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation
    Strumidlo, Agnieszka
    Skiba, Sylwia
    Scott, Rodney J.
    Lubinski, Jan
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2017, 15
  • [49] The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation
    Agnieszka Strumidło
    Sylwia Skiba
    Rodney J. Scott
    Jan Lubiński
    Hereditary Cancer in Clinical Practice, 15
  • [50] Newly diagnosed advanced Ovarian Cancer with BRCA-Mutations Prolonged progression-free Survival with Olaparib film-coated Tablets
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (09) : 487 - 487
12345